Recombinant activated factor Ⅶ for coagulopathy in patients with severe multiple injuries
10.3760/cma.j.issn.1001-8050.2013.07.004
- VernacularTitle:重组活化Ⅶ因子在严重多发伤凝血功能障碍中的应用
- Author:
Guangbin HUANG
;
Pan WANG
;
Ping HE
;
Ping HU
- Publication Type:Journal Article
- Keywords:
Multiple trauma;
Shock,hemorrhagic;
Blood coagulation disorders;
Recombinant activated factor Ⅶ
- From:
Chinese Journal of Trauma
2013;29(7):588-590
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect of recombinant activated factor Ⅶ (rⅦa) in treatment of hemorrhagic shock after severe multiple injuries with coagulopathy.Methods Sixteen cases of coagulopathy after severe multiple injuries administered with rⅦa between July 2011 and June 2012 were reviewed.The requirements of blood product and coagulogram variation were comparatively studied before and after rⅦa therapy.Results After rⅦa therapy,bleeding was brought to a halt in 24 hours for nine cases and in 72 hours for seven cases.In the end,13 out of the 16 cases survived in the absence of myocardial infarct,cerebrovascular accident or deep vein thrombosis.Requirements of red blood cells,fresh frozen plasma,cryoprecipitate and platelet (PLT) were decreased at 48 hours after the final therapy as compared with those at 48 hours prior to the primary therapy,but statistical significance only existed in the reduction of fresh frozen plasma and cryoprecipitate (P ＜ 0.05).The coagulogram indices including prothrombin time (PT) and activated partial thromboplastin time (APTT) at 4 hours after the final therapy presented statistical differences from those prior to the primary therapy (P ＜ 0.05).Conclusion rⅦa is an important,effective and safe auxiliary means for surgical hemostasis of coagulopathy after severe multiple injuries.
